↓ Skip to main content

Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors

Overview of attention for article published in Cancer Discovery, May 2020
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#47 of 3,489)
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news
19 news outlets
blogs
1 blog
twitter
100 tweeters

Citations

dimensions_citation
121 Dimensions

Readers on

mendeley
125 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors
Published in
Cancer Discovery, May 2020
DOI 10.1158/2159-8290.cd-19-1014
Pubmed ID
Authors

Junji Tsurutani, Hiroji Iwata, Ian Krop, Pasi A. Jänne, Toshihiko Doi, Shunji Takahashi, Haeseong Park, Charles Redfern, Kenji Tamura, Trisha M. Wise-Draper, Kaku Saito, Masahiro Sugihara, Jasmeet Singh, Takahiro Jikoh, Gilles Gallant, Bob T. Li

Twitter Demographics

The data shown below were collected from the profiles of 100 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 125 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 125 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 26 21%
Other 15 12%
Student > Ph. D. Student 14 11%
Student > Postgraduate 12 10%
Unspecified 8 6%
Other 19 15%
Unknown 31 25%
Readers by discipline Count As %
Medicine and Dentistry 42 34%
Agricultural and Biological Sciences 9 7%
Biochemistry, Genetics and Molecular Biology 9 7%
Unspecified 7 6%
Pharmacology, Toxicology and Pharmaceutical Science 3 2%
Other 12 10%
Unknown 43 34%

Attention Score in Context

This research output has an Altmetric Attention Score of 195. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 August 2022.
All research outputs
#152,671
of 21,790,947 outputs
Outputs from Cancer Discovery
#47
of 3,489 outputs
Outputs of similar age
#4,806
of 294,022 outputs
Outputs of similar age from Cancer Discovery
#3
of 76 outputs
Altmetric has tracked 21,790,947 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,489 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 18.6. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 294,022 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 76 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.